Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1288

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 5
Chunk 1288
---
Market
Information

Our
common stock is listed on The Nasdaq Capital Market and its stock symbol is “JUNS.” The closing price of our common stock
on The Nasdaq Capital Market on March 28, 2025 was $0.70.

Holders

As
of March 28, 2025, there were 33,103,860 shares of common stock issued and outstanding, and we had approximately 31 holders
of record of our common stock.  The number of record holders does not include beneficial owners of common stock whose shares are
held in the names of banks, brokers, nominees or other fiduciaries.

Dividends

We
have not declared or paid any cash dividends on our common stock since our inception, and do not currently anticipate paying cash dividends
in the foreseeable future. We intend to retain future earnings, if any, for reinvestment in the development and expansion of our business.

Securities
Authorized for Issuance Under Equity Compensation Plans

The
Company’s stockholders approved the 2016 Equity Incentive Plan (“2016 Plan”) on January 4, 2016. Under the 2016 Plan,
as modified, 8,437,500 shares of common stock are authorized for issuance to employees, officers, directors, consultants. The 2016 Plan
authorizes the grant of nonqualified stock options and incentive stock options, restricted stock awards, restricted stock units, stock
appreciation rights, under the 2016 Plan. The Company does not intend to make any grants under the 2016 Plan.

The
Board of Directors and stockholders of the Company approved the 2021 Equity Incentive Plan (the “2021 Plan”) on September
17, 2021. Under the 2021 Plan, 1,125,000 shares of common stock are authorized for issuance to employees, directors and independent contractors
(except those performing services in connection with the offer or sale of the Company’s securities in a capital raising transaction,
or promoting or maintaining a market for the Company’s securities. The 2021 Plan authorizes equity-based and cash-based incentives
for participants. On July 22, 2022, the Board of Directors increased the shares authorized in the 2021 Plan, increasing the plan to 1,710,000.
The Company does not intend to make any grants under the 2021 Plan.

The
Board of Directors and stockholders of the Company approved the 2023 Equity In